Atlas Trials

An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

Clinical trial NCT07344818 · RECRUITING

Trial details

NCT number
NCT07344818
Sponsor
Peking University People's Hospital
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
R/R Aggressive B-cell Lymphoma
Start date
2026-01-07
Primary completion
2027-03-31
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.